These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23899335)

  • 1. The current state of pemetrexed in ovarian cancer.
    Miller RE; Banerjee S
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1201-10. PubMed ID: 23899335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed for the treatment of non-small cell lung cancer.
    Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
    Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed disodium in ovarian cancer treatment.
    Morotti M; Valenzano Menada M; Venturini PL; Mammoliti S; Ferrero S
    Expert Opin Investig Drugs; 2012 Apr; 21(4):437-49. PubMed ID: 22324304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
    Villela LR; Stanford BL; Shah SR
    Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed disodium for the treatment of NSCLC: an update.
    Hsu JY; Wakelee H
    Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
    Vergote I; Calvert H; Kania M; Kaiser C; Zimmermann AH; Sehouli J
    Eur J Cancer; 2009 May; 45(8):1415-23. PubMed ID: 19168349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
    Jones RJ; Twelves CJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed in malignant pleural mesothelioma.
    Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of pemetrexed.
    Sørensen JB
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):919-28. PubMed ID: 21599552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of a promising new agent--pemetrexed disodium.
    Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
    Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.